Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

FDA accelerated approval of iberdomide (Zenbexus) with daratumumab and hyaluronidase-fihj and dexamethasone

Accelerated approval on August 13, 2026, for adults with multiple myeloma after at least one prior line including a proteasome inhibitor and an immunomodulatory agent, in combination with daratumumab and hyaluronidase-fihj and dexamethasone. In the first 420 randomized patients (IberDd n=207 vs DVd n=213), MRD-negative CR at any time was 41% (95% CI 34-48) vs 21% (95% CI 15-27), p<0.0001. Continued approval may depend on confirmatory verification of clinical benefit. The trial remains ongoing for PFS.

FDA Cancer Approvals